Compare ANL & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ANL | NDMO |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Trusts Except Educational Religious and Charitable |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.3M | 604.7M |
| IPO Year | 2022 | 2019 |
| Metric | ANL | NDMO |
|---|---|---|
| Price | $11.72 | $10.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 333.5K | 106.9K |
| Earning Date | 04-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.02 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $9.57 |
| 52 Week High | $17.25 | $10.82 |
| Indicator | ANL | NDMO |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 39.09 |
| Support Level | $6.92 | $9.91 |
| Resistance Level | $12.09 | $10.49 |
| Average True Range (ATR) | 1.51 | 0.09 |
| MACD | -0.51 | -0.03 |
| Stochastic Oscillator | 20.81 | 25.00 |
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.